The Use of Zidovudine Pharmacophore in Multi-Target-Directed Ligands for AIDS Therapy

The concept of polypharmacology embraces multiple drugs combined in a therapeutic regimen (drug combination or cocktail), fixed dose combinations (FDCs), and a single drug that binds to different targets (multi-target drug). A polypharmacology approach is widely applied in the treatment of acquired immunodeficiency syndrome (AIDS), providing life-saving therapies for millions of people living with HIV. Despite the success in viral load suppression and patient survival of combined antiretroviral therapy (cART), the development of new drugs has become imperative, owing to the emergence of resistant strains and poor adherence to cART. 3′-azido-2′,3′-dideoxythymidine, also known as azidothymidine or zidovudine (AZT), is a widely applied starting scaffold in the search for new compounds, due to its good antiretroviral activity. Through the medicinal chemistry tool of molecular hybridization, AZT has been included in the structure of several compounds allowing for the development of multi-target-directed ligands (MTDLs) as antiretrovirals. This review aims to systematically explore and critically discuss AZT-based compounds as potential MTDLs for the treatment of AIDS. The review findings allowed us to conclude that: (i) AZT hybrids are still worth exploring, as they may provide highly active compounds targeting different steps of the HIV-1 replication cycle; (ii) AZT is a good starting point for the preparation of co-drugs with enhanced cell permeability.

[1]  M. Reitz,et al.  Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients , 2021, Pharmaceutics.

[2]  M. Bartolini,et al.  From Combinations to Single-Molecule Polypharmacology—Cromolyn-Ibuprofen Conjugates for Alzheimer’s Disease , 2021, Molecules.

[3]  M. Mohan,et al.  Drug Repurposing Approaches to Combating Viral Infections , 2020, Journal of clinical medicine.

[4]  M. Bolognesi,et al.  α-Linolenic Acid–Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis , 2020, ACS medicinal chemistry letters.

[5]  Duan Liu,et al.  1,2,3‐Triazole hybrids with anti‐HIV‐1 activity , 2020, Archiv der Pharmazie.

[6]  Yanli Wang,et al.  Novel Betulinic Acid-Nucleoside Hybrids with Potent Anti-HIV Activity. , 2020, ACS medicinal chemistry letters.

[7]  Zhi Xu.  1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). , 2020, European journal of medicinal chemistry.

[8]  Claudia Albertini,et al.  From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology , 2020, Medicinal research reviews.

[9]  R. Nasr,et al.  Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma , 2020, Frontiers in Microbiology.

[10]  Zhi Xu,et al.  1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. , 2019, European journal of medicinal chemistry.

[11]  A. Estévez-Braun,et al.  Synthesis and Antiplasmodial Activity of 1,2,3-Triazole-Naphthoquinone Conjugates , 2019, Molecules.

[12]  H. Aisa,et al.  1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview , 2019, Bioorganic & Medicinal Chemistry.

[13]  Maria Laura Bolognesi,et al.  Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. , 2019, Current topics in medicinal chemistry.

[14]  E. A. Popova,et al.  Synthesis and in vitro Biological Evaluation of Novel Thymidine Analogs Containing 1H-1,2,3-Triazolyl, 1H-Tetrazolyl, and 2H-Tetrazolyl Fragments , 2019, Nucleosides, nucleotides & nucleic acids.

[15]  Albert-László Barabási,et al.  Network-based prediction of drug combinations , 2019, Nature Communications.

[16]  Maria Laura Bolognesi,et al.  Harnessing Polypharmacology with Medicinal Chemistry. , 2019, ACS medicinal chemistry letters.

[17]  R. Gulick,et al.  HIV treatment and prevention 2019: current standards of care. , 2019, Current opinion in HIV and AIDS.

[18]  T. Souza,et al.  New Efavirenz Derivatives and 1,2,3-Triazolyl-phosphonates as Inhibitors of Reverse Transcriptase of HIV-1. , 2018, Current topics in medicinal chemistry.

[19]  S. de Castro,et al.  Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy? , 2018, European journal of medicinal chemistry.

[20]  S. Hernández-Díaz,et al.  Zidovudine use in pregnancy and congenital malformations , 2017, AIDS.

[21]  Virender Singh,et al.  Medicinal attributes of 1,2,3-triazoles: Current developments. , 2017, Bioorganic chemistry.

[22]  Alan Talevi,et al.  Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective , 2015, Front. Pharmacol..

[23]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[24]  Hongmin Li,et al.  5'-Silylated 3'-1,2,3-triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus. , 2015, Journal of medicinal chemistry.

[25]  H. Truong,et al.  New hybrids between triterpenoid acids and nucleoside HIV-RT inhibitors , 2015 .

[26]  N. Tuyet,et al.  Synthesis and cytotoxic evaluation of novel amide–triazole-linked triterpenoid–AZT conjugates , 2015 .

[27]  M. D’hooghe,et al.  Synthesis and cytotoxic evaluation of novel ester-triazole-linked triterpenoid-AZT conjugates. , 2014, Bioorganic & medicinal chemistry letters.

[28]  M. Bolognesi,et al.  Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases , 2014 .

[29]  Jeana Zacharias,et al.  Synthesis and antiviral evaluation of 4′-(1,2,3-triazol-1-yl)thymidines , 2014 .

[30]  M. Parniak,et al.  Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus. , 2013, Journal of medicinal chemistry.

[31]  G. Schmeda-Hirschmann,et al.  1,2,3-Triazole-Substituted Oleanolic Acid Derivatives: Synthesis and Antiproliferative Activity , 2013, Molecules.

[32]  P. R. Sharma,et al.  Synthesis of 3-O-propargylated betulinic acid and its 1,2,3-triazoles as potential apoptotic agents. , 2013, European journal of medicinal chemistry.

[33]  P. T. Kaye,et al.  Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors. , 2013, Bioorganic & medicinal chemistry.

[34]  M L Bolognesi,et al.  Polypharmacology in a single drug: multitarget drugs. , 2013, Current medicinal chemistry.

[35]  P. Pennings.  HIV Drug Resistance: Problems and Perspectives , 2012, Infectious disease reports.

[36]  Vipan Kumar,et al.  Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy. , 2012, Bioorganic & medicinal chemistry.

[37]  Chin-Ho Chen,et al.  Anti-AIDS agents 88. Anti-HIV conjugates of betulin and betulinic acid with AZT prepared via click chemistry. , 2012, Tetrahedron letters.

[38]  D. Hazuda,et al.  HIV-1 antiretroviral drug therapy. , 2012, Cold Spring Harbor perspectives in medicine.

[39]  C. Edelstein,et al.  Effect of nucleoside and nucleotide analog reverse transcriptase inhibitors on cell-mediated immune functions. , 2011, AIDS research and human retroviruses.

[40]  I. Alabugin,et al.  Rapid access to new bioconjugates of betulonic acid via click chemistry. , 2011, Bioorganic & medicinal chemistry letters.

[41]  Chin-Ho Chen,et al.  Conjugates of betulin derivatives with AZT as potent anti-HIV agents. , 2010, Bioorganic & medicinal chemistry.

[42]  S. Broder,et al.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. , 2010, Antiviral research.

[43]  P. Yogeeswari,et al.  Synthesis of Zidovudine Derivatives with anti-HIV-1 and Antibacterial Activities. , 2009 .

[44]  Honglin Li,et al.  Synthesis of glucoconjugates of oleanolic acid as inhibitors of glycogen phosphorylase. , 2009, Carbohydrate research.

[45]  P. Yogeeswari,et al.  Synthesis of Zidovudine Derivatives with Anti-HIV-1 and Antibacterial Activities , 2009, Nucleosides, nucleotides & nucleic acids.

[46]  C. Pannecouque,et al.  Dipeptide Derivatives of AZT: Synthesis, Chemical Stability, Activation in Human Plasma, hPEPT1 Affinity, and Antiviral Activity , 2008, ChemMedChem.

[47]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[48]  D. Montefiori,et al.  Betulinic Acid Derivatives That Target gp120 and Inhibit Multiple Genetic Subtypes of Human Immunodeficiency Virus Type 1 , 2007, Antimicrobial Agents and Chemotherapy.

[49]  David E. Martin,et al.  Determinants of activity of the HIV-1 maturation inhibitor PA-457. , 2006, Virology.

[50]  R. Pennell,et al.  HIV/AIDS , 2006 .

[51]  E. De Clercq,et al.  Synthesis and Antiviral Activities of 1,2,3-triazole Functionalized Thymidines: 1,3-dipolar Cycloaddition for Efficient Regioselective Diversity Generation , 2005, Antiviral chemistry & chemotherapy.

[52]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[53]  E. De Clercq,et al.  Chemoenzymatic Syntheses of Homo‐ and Heterodimers of AZT and d4T, and Evaluation of Their Anti‐HIV Activity , 2004, Nucleosides, nucleotides & nucleic acids.

[54]  Y. Kiso,et al.  Synthesis and biological evaluation of prodrug-type anti-HIV agents: ester conjugates of carboxylic acid-containing dipeptide HIV protease inhibitors and a reverse transcriptase inhibitor. , 2001, Bioorganic & medicinal chemistry.

[55]  C. Nguyen,et al.  Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase. , 2000, Journal of medicinal chemistry.

[56]  J. Balzarini,et al.  Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region , 1999 .

[57]  Y. Kiso,et al.  A new class of anti-HIV agents: synthesis and activity of conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor. , 1999, Bioorganic & medicinal chemistry letters.

[58]  E. De Clercq,et al.  Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region. , 1999, Journal of Medicinal Chemistry.

[59]  J. Vacca,et al.  The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor. , 1998, Pharmaceutical biotechnology.

[60]  K. Lee,et al.  Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. , 1997, Bioorganic & medicinal chemistry.

[61]  B. Styrt,et al.  Clinical toxicity of antiretroviral nucleoside analogs. , 1996, Antiviral research.

[62]  M. Baba,et al.  Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. , 1996, Antiviral research.

[63]  E. De Clercq,et al.  Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry. , 1996, Journal of medicinal chemistry.

[64]  D. Back,et al.  Metabolism of Zidovudine. , 1995, General pharmacology.

[65]  E. De Clercq,et al.  Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. , 1995, Journal of medicinal chemistry.

[66]  E. De Clercq,et al.  Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. , 1993, Journal of medicinal chemistry.

[67]  L. Resnick,et al.  Nucleotide dimers suppress HIV expression in vitro. , 1988, AIDS research and human retroviruses.

[68]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.